H.C. Wainwright Downgrades Summit Therapeutics Amid Merck's Sac-TMT Trial Data

H.C. Wainwright downgraded Summit Therapeutics (SMMT) from Buy to Neutral due to concerns over a late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck in collaboration with Kelun-Biotech.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · May 22, 2026, 15:46 UTC

H.C. Wainwright Downgrades Summit Therapeutics Amid Merck's Sac-TMT Trial Data

Tickers: $MRK $SMMT

Topics: Biotech Pharmaceuticals Stock Downgrades

Read the full article at Seeking Alpha

More World news

Donald Trump Suggests Tim Cook as Potential Successor for Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 16:09 UTC
Yankees President Randy Levine Advocates for Protect College Sports Act and Addresses MLB Labor Uncertainty CNBC · November 12, 2026, 15:34 UTC
Donald Trump Suggests Apple Chairman Tim Cook as Potential Successor to Nvidia CEO Jensen Huang TechCrunch · November 12, 2026, 16:12 UTC
Bybit Announces Title Partnership for Inaugural Stockholm Open ATP 250 Tournament PR Newswire · November 12, 2026, 16:11 UTC
SES AI Reports Q3 2026 Revenue Growth Amid Strategic Shift Toward Drone Battery Market Motley Fool · November 12, 2026, 16:10 UTC
Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC